MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)

微粉化阿托伐醌和阿奇霉素 (AT/AZ) 与 (TMP/SMX) 相比

• 批准号: 6303760
• 负责人: Andrea A.Z. Kovacs
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303760
• 关键词: AIDS therapy; HIV infections; adolescence (12-20); antiAIDS agent; antibacterial agents; atovaquone; azithromycin; bacterial disease; chemoprevention; child (0-11); clinical research; combination chemotherapy; dosage forms; drug screening /evaluation; human subject; human therapy evaluation; opportunistic infections; pharmacokinetics; sulfamethoxazole; thymidine monophosphate

The purpose of this study is to compare the combination of azithromycin plus atovaquone to TMP/SMX in preventing serious bacterial infections in children age 2-18 who are HIV-infected. THis study also compares long-term safety and tolerance of these drugs.

本研究的目的是比较阿奇霉素加阿托伐醌与 TMP/SMX 联合用药在预防 2-18 岁 HIV 感染儿童严重细菌感染方面的效果。 这项研究还比较了这些药物的长期安全性和耐受性。